Hyderabad-headquartered Aurobindo Pharma Limited on Monday entered into licensing and supply agreements with AstraZeneca, a global pharmaceutical and biologics company headquartered in London, to supply finished dosage and sterile products to emerging markets.
“The agreement will support AstraZeneca’s investment in branded generics sold in emerging markets, and these products fall under a broad range of therapeutic segments such as anti-infective, cardiovascular system (CVS) and central nervous system (CNS),” the company said in a press release.
Aurobindo Pharma chairman, PV Ramprasad Reddy, stated that the strategic agreements with AstraZeneca would accelerate the company's growth plans and support its earnings. He, however, did not disclose the financial details.
"These agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business", AstraZeneca head of branded generics operations, Kaushik Banerjee, said.
